AstraZeneca and Amgen's Tezspire significantly reduced nasal congestion and polyp size in a Phase 3 trial for chronic rhinosinusitis, potentially expanding its approved uses.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.